S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
S&P 500   4,179.83 (-0.61%)
DOW   32,908.27 (-0.41%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NYSE:QGEN

Qiagen (QGEN) Stock Forecast, Price & News

$45.16
-0.13 (-0.29%)
(As of 05/31/2023 ET)
Compare
Today's Range
$44.85
$45.32
50-Day Range
$43.93
$46.76
52-Week Range
$40.38
$51.18
Volume
1.06 million shs
Average Volume
758,947 shs
Market Capitalization
$10.28 billion
P/E Ratio
29.32
Dividend Yield
N/A
Price Target
$54.87

Qiagen MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
21.5% Upside
$54.87 Price Target
Short Interest
Healthy
1.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.24mentions of Qiagen in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.55%
From $2.12 to $2.28 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

235th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

32nd out of 167 stocks


QGEN stock logo

About Qiagen (NYSE:QGEN) Stock

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Stock News Headlines

3 Medical Stocks Rated BUY
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Kepler Capital Keeps Their Hold Rating on Qiagen (QGEN)
Qiagen (NYSE:QGEN) Upgraded by Morgan Stanley to Overweight
StockNews.com Initiates Coverage on Qiagen (NASDAQ:QGEN)
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
QGEN Qiagen N.V.
Qiagen NV QGEN Stock Quote
Qiagen (QGEN) Q1 Earnings Beat Estimates
(QGEN) & Its Rivals Head-To-Head Review
QIAGEN announces expansion of Supervisory Board
Reviewing Qiagen (QGEN) & Its Rivals
See More Headlines
Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Company Calendar

Last Earnings
5/03/2023
Today
5/31/2023
Next Earnings (Estimated)
7/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Employees
6,178
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.87
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+21.5%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$423.21 million
Pretax Margin
21.31%

Debt

Sales & Book Value

Annual Sales
$2.14 billion
Cash Flow
$3.40 per share
Book Value
$15.64 per share

Miscellaneous

Free Float
207,222,000
Market Cap
$10.28 billion
Optionable
Optionable
Beta
0.39

Key Executives

  • Thierry Bernard
    Chief Executive Officer & Managing Director
  • Antonio Santos
    Senior Vice President & Head-Global Operations
  • Roland Sackers
    Chief Financial Officer & Managing Director
  • Philipp von Hugo
    VP, Head-Global Legal Affairs & Compliance
  • Lezette Young
    Manager-Compliance & Legal













QGEN Stock - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" QGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QGEN, but not buy additional shares or sell existing shares.
View QGEN analyst ratings
or view top-rated stocks.

What is Qiagen's stock price forecast for 2023?

5 Wall Street research analysts have issued 12 month price objectives for Qiagen's stock. Their QGEN share price forecasts range from $50.00 to $60.00. On average, they expect the company's stock price to reach $54.87 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price.
View analysts price targets for QGEN
or view top-rated stocks among Wall Street analysts.

How have QGEN shares performed in 2023?

Qiagen's stock was trading at $49.87 at the beginning of the year. Since then, QGEN shares have decreased by 9.4% and is now trading at $45.16.
View the best growth stocks for 2023 here
.

Are investors shorting Qiagen?

Qiagen saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 3,130,000 shares, a decline of 20.6% from the April 15th total of 3,940,000 shares. Based on an average daily volume of 779,200 shares, the days-to-cover ratio is presently 4.0 days. Currently, 1.4% of the shares of the stock are sold short.
View Qiagen's Short Interest
.

When is Qiagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our QGEN earnings forecast
.

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) posted its quarterly earnings data on Wednesday, May, 3rd. The company reported $0.51 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.04. The business had revenue of $485.40 million for the quarter, compared to the consensus estimate of $478.23 million. Qiagen had a trailing twelve-month return on equity of 14.08% and a net margin of 17.66%. The firm's revenue was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.80 EPS.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of $2.10- for the period, compared to the consensus earnings per share estimate of $2.10. The company issued revenue guidance of $2.05B-, compared to the consensus revenue estimate of $2.06 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.36%), FIL Ltd (1.35%), DekaBank Deutsche Girozentrale (1.27%), Perpetual Ltd (1.23%), Arrowstreet Capital Limited Partnership (1.22%) and Wellington Management Group LLP (1.21%).

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $45.16.

How much money does Qiagen make?

Qiagen (NYSE:QGEN) has a market capitalization of $10.28 billion and generates $2.14 billion in revenue each year. The company earns $423.21 million in net income (profit) each year or $1.54 on an earnings per share basis.

How many employees does Qiagen have?

The company employs 6,178 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912. The official website for the company is www.qiagen.com. The company can be reached via phone at (177) 355-6600, via email at ir@qiagen.com, or via fax at 31-77-355-6658.

This page (NYSE:QGEN) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -